Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
BioPharmaLinx AB
AB
Active
Org 5567684401
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2008 · 17 years old
0 employees
Monitor
Share
Sweden
/
Companies
/
Research and experimental development on natural sciences and engineering
/
BioPharmaLinx AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
2M
2M
1M
1M
0M
2021: 2M
2M
2021
2022: 2M (0% vs 2021)
2M
0%
2022
2023: 1M (-50% vs 2022)
1M
-50%
2023
2024: 0M (-100% vs 2023)
0M
-100%
2024
2025: 0M
0M
2025
EBITDA
SEK millions
1M
1M
1M
0M
0M
2021: 1M
1M
2021
2022: 0M (-100% vs 2021)
0M
-100%
2022
2023: 0M
0M
2023
2024: 0M
0M
2024
2025: 0M
0M
2025
Income statement
SEK thousands
Item
2025
2024
2023
2022
2021
Revenue
0
400
1 319
1 887
1 696
Staff expenses
−0
−269
—
−430
—
EBITDA
−30
−40
−366
375
715
Depreciation & amort.
—
—
−110
−122
−132
EBIT
−30
−40
−476
252
583
Net financials
5
7
11
45
218
Profit before tax
−26
468
245
898
1 101
Tax
—
−111
−79
−205
−249
Net profit
−26
356
166
693
852
Balance sheet
SEK thousands
Item
2025
2024
2023
2022
2021
Total assets
8 658
8 932
9 358
10 226
10 054
Equity
8 530
8 760
8 599
8 620
8 111
Long-term debt
—
—
0
—
0
Short-term debt
128
173
259
396
133
Total debt
128
173
259
396
133
Financial ratios
5-year trend
EBITDA margin
<−999 %
This company
15,8 %
Market median
This company
Market median
>999% below market
2021
2025
Equity ratio
98,5 %
This company
38,2 %
Market median
This company
Market median
158% above market
2021
2025
Return on equity
−0,3 %
This company
18,4 %
Market median
This company
Market median
102% below market
2021
2025
Net profit margin
<−999 %
This company
8,1 %
Market median
This company
Market median
>999% below market
2021
2025
Asset turnover
0,00×
This company
1,12×
Market median
This company
Market median
100% below market
2021
2025
Debt / equity
0,02×
This company
0,62×
Market median
This company
Market median
97% below market
2021
2025
Annual reports & filings
Annual report 2025
Filed via Bolagsverket / SCB · Period 2024-09-01 – 2025-08-31
View
PDF
Annual report 2024
Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-08-31
View
PDF
More on BioPharmaLinx AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
